Sucrose stabilization of Respiratory Syncytial Virus (RSV) during nebulization and experimental infection

被引:12
作者
Grosz D.D. [1 ]
Van Geelen A. [1 ]
Gallup J.M. [1 ]
Hostetter S.J. [1 ]
Derscheid R.J. [1 ]
Ackermann M.R. [1 ]
机构
[1] Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State University, Ames, IA 50011-1250
基金
美国国家卫生研究院;
关键词
Nebulization; Respiratory Syncytial Virus; RSV; Sucrose;
D O I
10.1186/1756-0500-7-158
中图分类号
学科分类号
摘要
Background: Respiratory syncytial virus (RSV) is a common respiratory pathogen that can cause severe pneumonia. In vivo studies of RSV can be difficult due to variation in viral infection and disease severity in some animal models. Factors that may contribute to the variation are decreases in viral titer due to preparation and storage and method of virus administration. Nebulization is one method of RSV administration that provides even distribution of virus to all lung lobes; however, the exact quantity of the virus killed by nebulization is not defined. To test the hypothesis that sucrose enhances RSV stability and infectivity, a series of in vitro experiments were conducted with RSV strain Memphis 37 stored at varying concentrations (0%, 3%, 5%, 8%, 10%, 15%, and 20%) of sucrose as a possible cryo- and nebulization protectant. The optimal in vitro concentration was then assessed in vivo in a lamb model. Methods. Prior to titering the virus on HEp-2 cells, the various virus solutions were subjected to one freeze-thaw cycle and one nebulization cycle. Forty-eight hours after viral plating, infectious foci were detected and counted using immunofluorescent imaging. Titers were determined after freeze-thaw and after freeze-thaw followed by nebulization, then compared to the stock titers (before freezing) as well as to one another to determine the loss of infectivity. To further test this in vivo, lambs 2 to 3-days-old were infected via nebulization with RSV using inoculate containing either 20% sucrose or no sucrose followed by assessments of infection severity. Results: Nebulization of virus in 0% sucrose resulted in a 0.580 log reduction in infectivity while virus in 20% sucrose exhibited a 0.297 log reduction. In vivo studies demonstrated that 20% sucrose enhanced RSV lesions and antigen distribution. Conclusions: The data suggests that both nebulization and freeze-thawing of RSV in the absence of sucrose cause unacceptable losses in viral infectivity and that sucrose acts as a RSV protectant in both regards. © 2014 Grosz et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 24 条
  • [1] Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., O'Brien K.L., Roca A., Wright P.F., Bruce N., Chandran A., Theodoratou E., Sutanto A., Sedyaningsih E.R., Ngama M., Munywoki P.K., Kartasasmita C., Simoes A.F., Rudan I., Weber M.W., Campbell H., Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis, Lancet, 375, pp. 1545-1555, (2010)
  • [2] Acute Respiratory Infections (Update September 2009). 2009 09/09 [Cited 2013]
  • [3] Collins P.L., Melero J.A., Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years, Virus Res, 162, pp. 80-99, (2011)
  • [4] Garcia C.G., Bhore R., Soriano-Fallas A., Trost M., Chason R., Ramilo O., Mejias A., Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis, Pediatrics, 126, (2010)
  • [5] Hon K.L., Leung T.F., Cheng W.Y., Ko N.M., Tang W.K., Wong W.W., Yeung W.H., Chan P.K., Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis, J Crit Care, 5, pp. 464-468, (2012)
  • [6] Sommer C., Resch B., Simoes E.A., Risk factors for severe respiratory syncytial virus lower respiratory tract infection, J Open Microbiol, 5, pp. 144-154, (2012)
  • [7] Welliver R.C., Checchia P.A., Bauman J.H., Fernandes A.W., Mahadevia P.J., Hall C.B., Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children, Curr Med Res Opin, 26, pp. 2175-2181, (2010)
  • [8] Abed Y., Boivin G., Treatment of respiratory virus infections, Antiviral Res, 70, pp. 1-16, (2006)
  • [9] Empey K.M., Peebles Jr. R.S., Kolls J.K., Pharmacologic advances in the treatment and prevention of respiratory syncytial virus, Clin Infect Dis, 50, pp. 1258-1267, (2010)
  • [10] Bem R.A., Domachowske J.B., Rosenberg H.F., Animal models of human respiratory syncytial virus disease, Am J Physiol Lung Cell Mol Physiol, 301, (2011)